EP2959894

NOVARTIS AG
Application Number
EP15177166A
Filing Date
Jun 25, 2007
Status
Granted And Under Opposition
Sep 9, 2022
Grant Date
Oct 12, 2022
External Links
Slate, Register

Biblio Summary

The patent EP2959894B1 was granted on Oct 12, 2022 by Novartis Ag The patent is currently Granted And Under Opposition.

The table below shows 23 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

DR. REDDY'S LABORATORIES LTD./ BETAPHARM ARZNEIMITTEL GMBHJul 12, 2023WITHDRAWN
GENERIS FARMACEUTICA S.A.Jul 12, 2023WITHDRAWN
ADAMED PHARMA S.A.Jul 11, 2023ADMISSIBLE
EGIS GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAGJul 11, 2023ADMISSIBLE
SYNTHON BVMay 22, 2023ADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBMay 10, 2023ADMISSIBLE
NEURAXPHARM ARZNEIMITTEL GMBHMar 22, 2023ADMISSIBLE
DR. SCHON, NEYMEYR & PARTNER PATENTANWALTE MBBJan 23, 2023ADMISSIBLE
BIOGARANJan 13, 2023ADMISSIBLE
STADAJan 9, 2023WITHDRAWN
BAUSCH HEALTH IRELAND LIMITEDJan 2, 2023WITHDRAWN
VIVANTA GENERICS S.R.O. / MSN LABRATORIES PRIVATE LTD.Dec 6, 2022ADMISSIBLE
HEUMANN PHARMA GMBH & CO. GENERICA KGDec 5, 2022ADMISSIBLE
ACCORD HEALTHCARE LTDDec 1, 2022WITHDRAWN
A-MED GMBHNov 21, 2022WITHDRAWN
RAFARM S.A.Nov 9, 2022ADMISSIBLE
GENEPHARM S.A.Nov 4, 2022ADMISSIBLE
ELPEN PHARMACEUTICAL CO. INC.Oct 20, 2022 N.A.
GLENMARK PHARMACEUTICALS EUROPE LTD.Oct 12, 2022ADMISSIBLE
PHARMATHEN S.A.Oct 12, 2022ADMISSIBLE
GENERICS UKOct 12, 2022WITHDRAWN
TEVAOct 12, 2022WITHDRAWN
ZENTIVA K.S.Oct 12, 2022WITHDRAWN

The table below shows the patents of Novartis Ag that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3124018Oral Formulations Of DeferasiroxApr 24, 20242
EP4159204Novel Pharmaceutical CompositionFeb 14, 20244
EP4159205Novel Pharmaceutical CompositionFeb 14, 20245